Gerresheimer’s Countdown to June: Audit, Short Sellers, and a €35 Million Accounting Hole

Gerresheimer faces multiple audits and a BaFin probe over disputed €35M revenue recognition; stock down 60% from peak; June audit crucial for debt covenants; insider buying signals confidence.

Gerresheimer is navigating one of the most intense regulatory sieges in German corporate memory. The BaFin, the audit watchdog APAS, and a second accounting firm are all trawling through its books simultaneously, with a clean June audit as the make-or-break event for the group’s borrowing arrangements. At the heart of the storm sits a disputed €35 million in bill-and-hold revenue recognition that KPMG, the group’s new auditor, passed without qualification for the 2024 financial year — a decision that has now triggered a professional misconduct probe by APAS. KPMG had only replaced Deloitte in 2024.

The immediate financial fallout has been severe. On Thursday, the stock fell 4% to €25.44, though other pricing data showed a sharper decline of 4.9% to €25.20. Even after a monthly rally of roughly 44–45%, the shares remain nearly 60% below their 52-week peak of €64.40. The relative strength index sits at 28, underscoring persistent market scepticism. Roughly 11% of reportable shares are still sold short, although some hedge funds have trimmed their positions, contributing to the recent recovery.

Management has bought itself some breathing room with creditors. Schuldschein holders approved a maturity extension to end?September 2026 by a massive 96% of the €870 million total volume, while banks have waived key leverage covenants through the third quarter. But those forbearances are conditional: an unqualified audit opinion for the 2025 annual report, due in June, is required to finalise the extensions. Only after that audit is published will Gerresheimer set a new date for its delayed annual general meeting. In a further bid to shore up credibility, the company has brought in Grant Thornton as a second auditor.

Alongside the accounting firefight, Gerresheimer is pushing ahead with the sale of its U.S. subsidiary Centor Inc., which makes packaging systems for prescription drugs and was carried on the books at €292 million at end?2024. Morgan Stanley is managing the process and a double-digit number of bidders have already emerged; Gerresheimer expects to close the transaction before the end of 2026. The irony is that Centor generates above-average margins, so divesting it will squeeze profitability further. The group nevertheless reaffirmed its 2026 guidance of €2.3–2.4 billion in revenue and an adjusted EBITDA margin of 18–19%, albeit with the caveat that the targets depend on successful credit negotiations and the outcome of the BaFin probe. The closure of the Chicago Heights glass plant is scheduled for the end of the fiscal year.

Inside the boardroom, sentiment tells a different story from the short?seller pessimism. Executives and large shareholders have recently bought nearly €9.7 million worth of stock, a strong vote of confidence that will be put to the test on 14 July 2026, when the half?year report lands. Should the half?year numbers validate the insider bets and the June audit clears the last of the accounting clouds, Gerresheimer may finally be able to write a new chapter — but for now, its recovery remains tethered to that one auditor’s signature.